The Injective (INJ) token surged 27% to nearly $9.20, its highest level in one year, pushing its market capitalization above $920 million. This rally followed a meeting in Washington between Injective CEO Eric Chen and officials from the White House, the SEC, and the CFTC focused on tokenization within the US regulatory framework. Technical analysts forecast continued upside momentum toward a $14 target, though the RSI near 80 indicates overbought conditions that could trigger a short-term correction.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
